Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACHV Stock Price Chart Interactive Chart >
ACHV Price/Volume Stats
| Current price | $5.38 | 52-week high | $8.13 |
| Prev. close | $5.20 | 52-week low | $2.00 |
| Day low | $5.03 | Volume | 85,100 |
| Day high | $5.38 | Avg. volume | 118,756 |
| 50-day MA | $3.43 | Dividend yield | N/A |
| 200-day MA | $4.43 | Market Cap | 96.29M |
Achieve Life Sciences, Inc. (ACHV) Company Bio
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV News From Around the Web
Below are the latest news stories about ACHIEVE LIFE SCIENCES INC that investors may wish to consider to help them evaluate ACHV as an investment opportunity.
Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma ConferenceSEATTLE, Wash and VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will participate in one-on-one meetings during the 2023 SVB Securities Global Biopharma Conference. The conference is taking place virtually from February 14-16, 2023. To arrange one-on-one meetings and for more information, please contact your SVB representative. For additional information on Achieve visit https://ir.achievelifesciences.com . About Achieve and Cytisinicline Achieve’s focus is to address the global smoking health and nicotine addiction epidemic through the developme... |
Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug (NASDAQ:ACHV)Achieve Life Sciences'' Phase 3 ORCA-3 registration trial is ongoing, and we expect the data readout in 2Q 2023. Read more to see my thoughts on ACHV stock. |
Achieve Life Sciences Announces Granting of New Hire Inducement AwardSEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued an inducement grant of stock options to a new employee. Achieve’s Board of Directors approved the new employment inducement grant to purchase 15,000 shares of Achieve’s commo |
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking CessationSEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the final subject of the Company’s Phase 3 ORCA-3 trial has completed treatment in the study. Similar to the previously reported ORCA-2 trial, ORCA-3 is evaluating the smoking cessation e |
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call TranscriptAchieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript November 14, 2022 Achieve Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, expectations were $-1.13. Operator: Good day, ladies and gentlemen, and welcome to Achieve Life Sciences Third Quarter 2022 Earnings Conference Call. All lines have been placed on a listen-only […] |
ACHV Price Returns
| 1-mo | 92.14% |
| 3-mo | 162.44% |
| 6-mo | 7.60% |
| 1-year | -28.65% |
| 3-year | -50.19% |
| 5-year | -98.08% |
| YTD | 119.59% |
| 2022 | -68.51% |
| 2021 | -3.95% |
| 2020 | -23.57% |
| 2019 | -56.21% |
| 2018 | -90.97% |
Loading social stream, please wait...